The effects of tislelizumab treatment on the health‐related quality of life of patients with advanced non‐small cell lung cancer

This study examined the health‐related quality of life (HRQoL) of patients with advanced non‐small cell lung cancer (NSCLC) receiving tislelizumab versus docetaxel in the open‐label, multicenter, Phase 3 trial called RATIONALE‐303 (NCT03358875). HRQoL was assessed with the EORTC QLQ‐C30, EORTC QLQ‐L...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Dingzhi, Zhou, Caicun, Barnes, Gisoo, Ma, Yiyuan, Li, Songzi, Zhan, Lin, Tang, Boxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501279/
https://www.ncbi.nlm.nih.gov/pubmed/37587845
http://dx.doi.org/10.1002/cam4.6361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501279/
https://www.ncbi.nlm.nih.gov/pubmed/37587845
http://dx.doi.org/10.1002/cam4.6361

Ejemplares similares